pmc logo image
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology

Formats:

Am J Pathol. 1990 February; 136(2): 421–428.
PMCID: PMC1877403
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
C. J. O'Hara, J. M. Corson, G. S. Pinkus, and R. A. Stahel
Department of Pathology, New England Deaconess Hospital, Boston, Massachusetts 02115.
Abstract
ME1 is a monoclonal antibody reactive in frozen tissue sections with normal mesothelial cells and malignant mesotheliomas. In this immunoperoxidase study, ME1 reacted with all 40 epithelial type malignant mesotheliomas. Fifty percent or more of the mesothelioma cells were stained in all cases and the staining intensity was strong in 32 and moderate in eight. In contrast, all 19 well- and moderately differentiated pulmonary adenocarcinomas were completely negative, and of the total 88 non-mesotheliomatous malignancies studied, staining comparable to the mesotheliomas was seen in only 6 tumors (2 pulmonary adenocarcinomas, 2 adenocarcinomas of the breast, 1 adenocarcinoma of the pancreas, and 1 melanoma), although limited, weaker staining was seen in additional cases. Five of the six strongly to moderately positive nonmesotheliomatous tumors had immunoreactivity for complementary immunoreactants (CEA, Leu-M1, S-100 protein, HMB-45). Our results with ME1, the first monoclonal antibody that recognizes malignant mesothelial cells, provides a basis for using this reagent in the differential diagnosis of tumors of the pleura and peritoneum.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Roggli VL, Kolbeck J, Sanfilippo F, Shelburne JD. Pathology of human mesothelioma. Etiologic and diagnostic considerations. Pathol Annu. 1987;22 Pt 2:91–131. [PubMed]
  • Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol. 1987 Jan;18(1):67–74. [PubMed]
  • Warhol MJ, Hickey WF, Corson JM. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. Am J Surg Pathol. 1982 Jun;6(4):307–314. [PubMed]
  • Coleman M, Henderson DW, Mukherjee TM. The ultrastructural pathology of malignant pleural mesothelioma. Pathol Annu. 1989;24 Pt 1:303–353. [PubMed]
  • Wang NS, Huang SN, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer. 1979 Sep;44(3):937–943. [PubMed]
  • Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol. 1982 Jul;108(1):80–88. [PubMed]
  • Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol. 1984 Apr;8(4):277–279. [PubMed]
  • Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Cancer. 1985 Apr 15;55(8):1679–1685. [PubMed]
  • Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 1989 Apr;13(4):276–291. [PubMed]
  • Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol. 1986 May;123(2):212–219. [PubMed]
  • Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am J Surg Pathol. 1987 Jun;11(6):445–456. [PubMed]
  • Szpak CA, Johnston WW, Roggli V, Kolbeck J, Lottich SC, Vollmer R, Thor A, Schlom J. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol. 1986 Feb;122(2):252–260. [PubMed]
  • Stahel RA, O'Hara CJ, Waibel R, Martin A. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Int J Cancer. 1988 Feb 15;41(2):218–223. [PubMed]
  • Kurtin PJ, Pinkus GS. Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum Pathol. 1985 Apr;16(4):353–365. [PubMed]
  • Marshall RJ, Herbert A, Braye SG, Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. J Clin Pathol. 1984 Nov;37(11):1215–1221. [PubMed]
  • Kahn HJ, Thorner PS, Yeger H, Bailey D, Baumal R. Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids, and mesotheliomas using polyclonal and monoclonal anti-keratin antibodies. Am J Clin Pathol. 1986 Nov;86(5):566–574. [PubMed]
  • Ghosh AK, Gatter KC, Dunnill MS, Mason DY. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. J Clin Pathol. 1987 Jan;40(1):19–25. [PubMed]
  • Tron V, Wright JL, Churg A. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Arch Pathol Lab Med. 1987 Mar;111(3):291–293. [PubMed]
  • Lee I, Radosevich JA, Chejfec G, Ma YX, Warren WH, Rosen ST, Gould VE. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Am J Pathol. 1986 Jun;123(3):497–507. [PubMed]
  • Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol. 1989 Jan;20(1):53–57. [PubMed]
  • Singh G, Whiteside TL, Dekker A. Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay. Cancer. 1979 Jun;43(6):2288–2296. [PubMed]
  • Donna A, Betta PG, Bellingeri D, Marchesini A. New marker for mesothelioma: an immunoperoxidase study. J Clin Pathol. 1986 Sep;39(9):961–968. [PubMed]
  • Donna A, Betta PG, Robutti F. Use of antimesothelial cell antibody and computer assisted quantitative analysis for distinguishing between reactive and neoplastic serosal tissues. J Clin Pathol. 1987 Dec;40(12):1428–1431. [PubMed]
  • Mazoujian G, Pinkus GS, Davis S, Haagensen DE., Jr Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983 Feb;110(2):105–112. [PubMed]
  • Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986 May;123(2):195–203. [PubMed]